Type 2 Diabetes News and Research

Latest Type 2 Diabetes News and Research

Santarus submits rifamycin SV MMX IND to the FDA

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) requesting approval to begin a Phase III clinical program evaluating rifamycin SV MMX® in patients with travelers’ diarrhea.

30 Dec 2009

Liraglutide FDA feedback expected within weeks, says Novo Nordisk

Novo Nordisk today announced that formal feedback from the United States Food and Drug Administration (FDA) regarding liraglutide, a once-daily human GLP-1 analogue, is expected within weeks.

30 Dec 2009

Pharmacists can reduce treatment costs and improve outcomes if given the chance

The role of pharmacists hasn't received much attention in the debate on the cost of health care. But national and regional studies show that when pharmacists directly participate in patient care, they significantly reduce treatment costs and improve outcomes.

30 Dec 2009

ADA recommends the A1C test for diabetes screening and diagnosis

New official guidelines for diabetes screening and diagnosis now include a blood test that gives a person's average blood glucose level over the previous 2-3 months.

30 Dec 2009

VIVUS submits a NDA to the FDA for obesity drug Qnexa

VIVUS, Inc., a biopharmaceutical company developing innovative, next-generation medical therapies to address unmet needs in obesity, diabetes and sexual health, announced today that a New Drug Application (NDA) has been submitted to the U.S. Food and Drug Administration (FDA) seeking approval of Qnexa, its investigational drug for the treatment of obesity, including weight loss and maintenance of weight loss, in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, dyslipidemia or central adiposity.

30 Dec 2009

Study suggests genetic variations predispose African-Americans to diabetes

For years, scientists have tried to determine the basis for discrepancies between race and the predisposition for development of diseases such as type II diabetes and cardiovascular disease. Could factors such as differences in lifestyle or access to health care play a role, or is there something else in play?

29 Dec 2009

American Diabetes Association recommends A1C test for diagnosing diabetes and identifying pre-diabetes

The American Diabetes Association's new Clinical Practice Recommendations being published as a supplement to the January issue of Diabetes Care call for the addition of the A1C test as a means of diagnosing diabetes and identifying pre-diabetes. The test has been recommended for years as a measure of how well people are doing to keep their blood glucose levels under control.

29 Dec 2009

Nutrient-rich foods for weight loss

For the majority of Americans who are unhappy with their weight at any given moment, the New Year brings mixed emotions: the renewed resolution to shed pounds and the challenge of learning how to eat right to reach those goals.

29 Dec 2009

Discovery of beta cell defending enzyme raises hope for new treatments against diabetes

Cells in your body are constantly churning out poisonous forms of oxygen (oxidants) and mopping them up with a countervailing force of proteins and chemicals (anti-oxidants).

28 Dec 2009

American Diabetes Association lauds passage of health reform in the Senate

The American Diabetes Association issues the following statement about the passing of HR 3590 The Patient Protection and Affordable Care Act.

24 Dec 2009

Study reveals genomic switches separate autoimmune disorders in different clusters

Genomic switches can predispose an individual to one set of autoimmune disorders but protect the same person against another set of them, scientists at Stanford University School of Medicine have found.

24 Dec 2009

Intervention strategy brings positive changes in type 2 diabetic patients

South Dakota State University research showed an intervention strategy based on the Native American spiritual concept of the Medicine Wheel brought positive changes for diabetics.

24 Dec 2009

High prevalence of type 2 diabetes may be linked to excess niacin intake

Facing the increasing prevalence of type 2 diabetes worldwide in the past few decades, one may ask what is wrong with humans. Geneticists tell us that the human genome has not changed markedly in such a short time.

23 Dec 2009

Niacin may not be beneficial for type 2 diabetic patients

High-density lipoprotein (HDL), known as "good" cholesterol, isn't as protective for people with type 2 diabetes, according to research reported in Circulation: Journal of the American Heart Association.

22 Dec 2009

Darbepoetin alfa does not reduce cardiovascular problem in anemic patients on dialysis

An international study authored by a UT Southwestern Medical Center researcher has concluded that the anemia drug darbepoetin alfa works no better than a placebo in several other applications previously thought to be promising.

22 Dec 2009

GI Dynamics' EndoBarrier non-surgical type 2 diabetes therapy receives European CE mark approval

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced that it has received European CE mark approval for the EndoBarrier™, a non-surgical therapy to treat type 2 diabetes and obesity. The CE marking (an acronym for the French "Conformite Europeenne") certifies that a product has met EU requirements for marketing in Europe. Clinical trials involving more than 270 patients have demonstrated the significant weight loss and diabetes improvement achieved with the EndoBarrier Gastrointestinal Liner.

22 Dec 2009

Arena Pharmaceuticals submits lorcaserin NDA to the FDA

Arena Pharmaceuticals, Inc. announced today that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for lorcaserin, Arena's internally discovered and developed drug candidate for weight management, including weight loss and maintenance of weight loss. The submission is based on an extensive data package from lorcaserin's clinical development program that includes 18 clinical trials totaling 8,576 patients.

22 Dec 2009

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

22 Dec 2009

Cost outweighs benefits of self-monitoring blood glucose test strips

Routine self-monitoring of blood glucose levels by people with type 2 diabetes who are not taking insulin is an ineffective use of health resources as the modest benefits are outweighed by the significant cost of test strips, suggest 2 studies http://www.cmaj.ca/embargo/cmaj091017.pdf and http://www.cmaj.ca/embargo/cmaj090765.pdf in CMAJ (Canadian Medical Association Journal) www.cmaj.ca .

22 Dec 2009

Jamie Oliver to receive the 2010 TED Prize

Jamie Oliver, celebrity chef and standard-bearer in the fight against obesity and other diet related issues, has been announced as the recipient of the 2010 TED Prize, an award granting recipients $100,000 and something much bigger - an opportunity to realize a wish to change the world.

22 Dec 2009